Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Surface feature-guided mapping of cerebral metabolic changes in cognitively normal and mildly impaired elderly.

Apostolova LG, Thompson PM, Rogers SA, Dinov ID, Zoumalan C, Steiner CA, Siu E, Green AE, Small GW, Toga AW, Cummings JL, Phelps ME, Silverman DH.

Mol Imaging Biol. 2010 Apr;12(2):218-24. doi: 10.1007/s11307-009-0247-7. Epub 2009 Jul 28.

2.

18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.

Knopman DS, Jack CR Jr, Wiste HJ, Lundt ES, Weigand SD, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Roberts RO, Boeve BF, Petersen RC.

Neurobiol Aging. 2014 Sep;35(9):2096-106. doi: 10.1016/j.neurobiolaging.2014.03.006. Epub 2014 Mar 11.

3.

Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.

Förster S, Yousefi BH, Wester HJ, Klupp E, Rominger A, Förstl H, Kurz A, Grimmer T, Drzezga A.

Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1927-36. doi: 10.1007/s00259-012-2230-9. Epub 2012 Aug 28.

PMID:
22926714
4.

Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).

de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, Tsui W, Kandil E, Scherer AJ, Roche A, Imossi A, Thorn E, Bobinski M, Caraos C, Lesbre P, Schlyer D, Poirier J, Reisberg B, Fowler J.

Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10966-71. Epub 2001 Aug 28.

5.

Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.

Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM.

Am J Psychiatry. 2002 May;159(5):738-45.

PMID:
11986126
6.

Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease.

Hunt A, Schönknecht P, Henze M, Seidl U, Haberkorn U, Schröder J.

Psychiatry Res. 2007 Jul 15;155(2):147-54. Epub 2007 May 23.

PMID:
17524628
7.

Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment.

Caselli RJ, Chen K, Lee W, Alexander GE, Reiman EM.

Arch Neurol. 2008 Sep;65(9):1231-6. doi: 10.1001/archneurol.2008.1.

PMID:
18779428
8.

Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild cognitive impairment: an FDG PET study.

Del Sole A, Clerici F, Chiti A, Lecchi M, Mariani C, Maggiore L, Mosconi L, Lucignani G.

Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1357-66. doi: 10.1007/s00259-008-0773-6. Epub 2008 Apr 17.

PMID:
18418593
9.

Post-carotid endarterectomy changes in cerebral glucose metabolism on (18)F-fluorodeoxyglucose positron emission tomography associated with postoperative improvement or impairment in cognitive function.

Yoshida K, Ogasawara K, Saura H, Saito H, Kobayashi M, Yoshida K, Terasaki K, Fujiwara S, Ogawa A.

J Neurosurg. 2015 Dec;123(6):1546-54. doi: 10.3171/2014.12.JNS142339. Epub 2015 Jul 31.

PMID:
26230467
10.

Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study.

Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A.

Eur J Nucl Med Mol Imaging. 2003 Aug;30(8):1104-13. Epub 2003 May 23.

PMID:
12764551
11.

Concordance between (99m)Tc-ECD SPECT and 18F-FDG PET interpretations in patients with cognitive disorders diagnosed according to NIA-AA criteria.

Ito K, Shimano Y, Imabayashi E, Nakata Y, Omachi Y, Sato N, Arima K, Matsuda H.

Int J Geriatr Psychiatry. 2014 Oct;29(10):1079-86. doi: 10.1002/gps.4102. Epub 2014 Mar 29.

PMID:
24687634
12.

Perceived loss of memory ability and cerebral metabolic decline in persons with the apolipoprotein E-IV genetic risk for Alzheimer disease.

Ercoli L, Siddarth P, Huang SC, Miller K, Bookheimer SY, Wright BC, Phelps ME, Small G.

Arch Gen Psychiatry. 2006 Apr;63(4):442-8.

PMID:
16585474
13.

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Långström B, Nordberg A.

Brain. 2006 Nov;129(Pt 11):2856-66. Epub 2006 Jul 19.

PMID:
16854944
14.

Statistical image analysis of cerebral glucose metabolism in patients with cognitive impairment following diffuse traumatic brain injury.

Kato T, Nakayama N, Yasokawa Y, Okumura A, Shinoda J, Iwama T.

J Neurotrauma. 2007 Jun;24(6):919-26.

PMID:
17600509
15.

Age-Related Sex-Specific Changes in Brain Metabolism and Morphology.

Kakimoto A, Ito S, Okada H, Nishizawa S, Minoshima S, Ouchi Y.

J Nucl Med. 2016 Feb;57(2):221-5. doi: 10.2967/jnumed.115.166439. Epub 2015 Nov 25.

16.

Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.

Laforce R Jr, Tosun D, Ghosh P, Lehmann M, Madison CM, Weiner MW, Miller BL, Jagust WJ, Rabinovici GD.

Neuroimage Clin. 2014 Mar 19;4:508-16. doi: 10.1016/j.nicl.2014.03.005. eCollection 2014.

17.

Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents.

Mosconi L, Rinne JO, Tsui WH, Murray J, Li Y, Glodzik L, McHugh P, Williams S, Cummings M, Pirraglia E, Goldsmith SJ, Vallabhajosula S, Scheinin N, Viljanen T, Någren K, de Leon MJ.

Neurobiol Aging. 2013 Jan;34(1):22-34. doi: 10.1016/j.neurobiolaging.2012.03.002. Epub 2012 Apr 11.

18.

Brain changes within the visuo-spatial attentional network in posterior cortical atrophy.

Cerami C, Crespi C, Della Rosa PA, Dodich A, Marcone A, Magnani G, Coppi E, Falini A, Cappa SF, Perani D.

J Alzheimers Dis. 2015;43(2):385-95. doi: 10.3233/JAD-141275.

PMID:
25114070
19.

Relationship between Alzheimer disease-like pattern of 18F-FDG and fasting plasma glucose levels in cognitively normal volunteers.

Ishibashi K, Onishi A, Fujiwara Y, Ishiwata K, Ishii K.

J Nucl Med. 2015 Feb;56(2):229-33. doi: 10.2967/jnumed.114.150045. Epub 2015 Jan 8.

20.

MCI patients declining and not-declining at mid-term follow-up: FDG-PET findings.

Pagani M, Dessi B, Morbelli S, Brugnolo A, Salmaso D, Piccini A, Mazzei D, Villavecchia G, Larsson SA, Rodriguez G, Nobili F.

Curr Alzheimer Res. 2010 Jun;7(4):287-94.

PMID:
19939228

Supplemental Content

Support Center